Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Drug Profile

Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Alternative Names: ASP 7373; Avian influenza (bird flu) vaccine - Protein Sciences Corporation/UMN Pharma; H7-rHA; HA vaccine for H5N1 (UMN 0501) - Protein Sciences Corporation; HA vaccine for H9N2 (UMN 0901) - Protein Sciences Corporation; Influenza A (H1N1) vaccine - Protein Sciences Corporation/Vaxine; Influenza A virus H5N1 vaccine - UMN Pharma; Influenza A virus H7N9 vaccine - Protein Sciences Corporation; Panblok; PanBlok; Panblok H1/2009; Panblok-H7; Pandemic H5N1 influenza vaccine - Protein Sciences Corporation/UMN Pharma; Pandemic influenza virus (swine flu) vaccine - Vaxine; Recombinant H5 (rH5) pandemic influenza vaccine (Panblok) - Protein Sciences Corporation; Recombinant haemagglutinin (rHA) influenza vaccine; UMN 0901; UMN-0501

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Ildong Pharmaceutical; Protein Sciences Corporation; UMN Pharma; Vaxine
  • Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza A virus H9N2 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
  • No development reported Influenza A virus H1N1 subtype; Influenza A virus H9N2 subtype

Most Recent Events

  • 09 Apr 2024 Vaxine plans a phase I trial for COVID-2019 infections (Prevention, Monotherapy, Combination therapy) in Australia (Sublingual) (NCT06355232)
  • 13 Feb 2024 Sanofi completes a phase II trial in Influenza A virus H7N9 subtype (Prevention) in USA (IM) (NCT05608005)
  • 03 Nov 2022 Phase-II clinical trials in Influenza A virus H7N9 subtype (Prevention) in USA (IM) (NCT05608005)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top